IMAC (IMAC) Competitors $0.05 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. ATNF, SNPX, QNRX, LIPO, ADXS, XWEL, MOVE, INM, MYNZ, and BGLCShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include 180 Life Sciences (ATNF), Synaptogenix (SNPX), Quoin Pharmaceuticals (QNRX), Lipella Pharmaceuticals (LIPO), Ayala Pharmaceuticals (ADXS), XWELL (XWEL), Movano (MOVE), InMed Pharmaceuticals (INM), Mainz Biomed (MYNZ), and BioNexus Gene Lab (BGLC). These companies are all part of the "medical" sector. IMAC vs. Its Competitors 180 Life Sciences Synaptogenix Quoin Pharmaceuticals Lipella Pharmaceuticals Ayala Pharmaceuticals XWELL Movano InMed Pharmaceuticals Mainz Biomed BioNexus Gene Lab IMAC (NASDAQ:IMAC) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the media prefer IMAC or ATNF? In the previous week, IMAC had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 4 mentions for IMAC and 2 mentions for 180 Life Sciences. IMAC's average media sentiment score of 0.09 beat 180 Life Sciences' score of 0.00 indicating that IMAC is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IMAC 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 180 Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IMAC or ATNF more profitable? 180 Life Sciences has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% 180 Life Sciences N/A -147.32%-76.99% Do insiders & institutionals believe in IMAC or ATNF? 24.3% of IMAC shares are held by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 0.2% of 180 Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, IMAC or ATNF? 180 Life Sciences has lower revenue, but higher earnings than IMAC. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M0.09-$10.54MN/AN/A180 Life SciencesN/AN/A-$6.17MN/AN/A Which has more volatility & risk, IMAC or ATNF? IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. SummaryIMAC beats 180 Life Sciences on 7 of the 10 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32M$1.06M$5.53B$9.05BDividend YieldN/AN/A5.24%4.03%P/E RatioN/AN/A27.5220.22Price / Sales0.090.09421.02118.64Price / CashN/AN/A36.8958.07Price / Book0.070.078.045.67Net Income-$10.54M-$10.54M$3.18B$249.13M7 Day PerformanceN/AN/A2.90%3.28%1 Month PerformanceN/AN/A3.70%5.55%1 Year PerformanceN/AN/A36.15%21.12% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.05flatN/A-97.0%$1.32M$15.22M0.00106News CoverageATNF180 Life Sciences0.6066 of 5 stars$0.93+7.2%N/A-44.5%$5.28MN/A0.007Gap UpSNPXSynaptogenix1.1966 of 5 stars$3.77+5.2%$14.00+271.7%+109.4%$5.22MN/A-0.374Gap DownQNRXQuoin Pharmaceuticals0.5382 of 5 stars$8.84+3.0%N/A-55.2%$5.22MN/A-0.184Gap UpLIPOLipella Pharmaceuticals1.356 of 5 stars$1.16+5.5%N/A-77.9%$5.19M$540K-0.284ADXSAyala PharmaceuticalsN/A$0.12flatN/A-41.6%$5.13M$3.24M-0.0220XWELXWELL0.7435 of 5 stars$0.96+1.1%N/A-45.0%$5.05M$33.90M-0.24360Positive NewsMOVEMovano2.8917 of 5 stars$0.71+2.8%$30.00+4,137.3%-85.4%$4.98M$1.01M-0.1730Trending NewsINMInMed Pharmaceuticals1.0687 of 5 stars$4.06+65.8%N/A-42.8%$4.91M$4.92M-0.3410Analyst UpgradeGap UpHigh Trading VolumeMYNZMainz Biomed2.7735 of 5 stars$1.44+3.2%$14.00+875.6%-89.3%$4.89M$890K-0.0230Gap UpBGLCBioNexus Gene Lab0.4411 of 5 stars$2.71-1.3%N/A+33.5%$4.87M$9.51M0.0030Gap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors Synaptogenix Competitors Quoin Pharmaceuticals Competitors Lipella Pharmaceuticals Competitors Ayala Pharmaceuticals Competitors XWELL Competitors Movano Competitors InMed Pharmaceuticals Competitors Mainz Biomed Competitors BioNexus Gene Lab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
